Various embodiments of the invention relate to compositions comprising vitamins, minerals and trace elements, antioxidants, amino acids, probiotics, and other components and methods for using such compositions to treat or prevent diseases associated with oxidative stress, including cardiovascular disease.

Various embodiments of the invention relate to compositions comprising vitamins, minerals and trace elements, antioxidants, amino acids, probiotics, and other components and methods for using such compositions to treat or prevent diseases associated with oxidative stress, including cardiovascular disease.

Various embodiments of the invention relate to compositions comprising vitamins, minerals and trace elements, antioxidants, amino acids, probiotics, and other components and methods for using such compositions to treat or prevent diseases associated with oxidative stress, including cardiovascular disease.

The present disclosure relates to compositions comprising a range of ingredients suitable for use in adjusting and/or treating a companion animal such as a canid (e.g. a dog) or a feline (e.g. a cat) and their microbiomes, monitoring tools, and diagnostic methods for determining the health of a companion animal and their microbiome.

The present disclosure relates to compositions comprising a range of ingredients suitable for use in adjusting and/or treating a companion animal such as a canid (e.g. a dog) or a feline (e.g. a cat) and their microbiomes, monitoring tools, and diagnostic methods for determining the health of a companion animal and their microbiome.

A composition containing a plurality of particles containing a core having a lipid matrix including an active ingredient dispersed therein is disclosed. The active ingredient can include a fat-soluble active ingredient. The particles can be contained in a capsule. Also provided are methods for producing a pharmaceutical composition containing a plurality of particles containing a core having a lipid matrix including an active ingredient dispersed therein.

A composition containing a plurality of particles containing a core having a lipid matrix including an active ingredient dispersed therein is disclosed. The active ingredient can include a fat-soluble active ingredient. The particles can be contained in a capsule. Also provided are methods for producing a pharmaceutical composition containing a plurality of particles containing a core having a lipid matrix including an active ingredient dispersed therein.

This disclosure provides a composition and a method for enhancing urolithin B production. As a result of this, due to known impact of urolithin B, this can enhance reverse cholesterol transport and HDL function and management of plasma lipid profile through enhanced production of urolithin B from pomegranate polyphenols by administering a composition comprising a synergistic mixture of pomegranate polyphenols, lycopene and quercetin. The improved HDL function and lipid profile of such composition may be attributed to the enhanced urolithin B production made possible by the combination. Increasing the levels of urolithin B through modulation of the intestinal microbiome metabolism of pomegranate polyphenols is a potential therapeutic target for managing these diseases.

This disclosure provides a composition and a method for enhancing urolithin B production. As a result of this, due to known impact of urolithin B, this can enhance reverse cholesterol transport and HDL function and management of plasma lipid profile through enhanced production of urolithin B from pomegranate polyphenols by administering a composition comprising a synergistic mixture of pomegranate polyphenols, lycopene and quercetin. The improved HDL function and lipid profile of such composition may be attributed to the enhanced urolithin B production made possible by the combination. Increasing the levels of urolithin B through modulation of the intestinal microbiome metabolism of pomegranate polyphenols is a potential therapeutic target for managing these diseases.

This disclosure provides a composition and a method for enhancing urolithin B production. As a result of this, due to known impact of urolithin B, this can enhance reverse cholesterol transport and HDL function and management of plasma lipid profile through enhanced production of urolithin B from pomegranate polyphenols by administering a composition comprising a synergistic mixture of pomegranate polyphenols, lycopene and quercetin. The improved HDL function and lipid profile of such composition may be attributed to the enhanced urolithin B production made possible by the combination. Increasing the levels of urolithin B through modulation of the intestinal microbiome metabolism of pomegranate polyphenols is a potential therapeutic target for managing these diseases.